Panos Kanavos
Panos Kanavos
Associate Professor in International Health Policy
Подтвержден адрес электронной почты в домене lse.ac.uk - Главная страница
Название
Процитировано
Процитировано
Год
The rising burden of cancer in the developing world
P Kanavos
Annals of oncology 17, viii15-viii23, 2006
5772006
Assessing the economic challenges posed by orphan drugs
MF Drummond, DA Wilson, P Kanavos, P Ubel, J Rovira
International journal of technology assessment in health care 23 (1), 36-42, 2007
3142007
Encouraging the use of generic medicines: implications for transition economies
DR King, P Kanavos
Croatian medical journal 43 (4), 462-469, 2002
2532002
Ensuring value for money in health care: the role of health technology assessment in the European Union
C Sorenson, M Drummond, P Kanavos
WHO Regional Office Europe, 2008
2412008
Diabetes expenditure, burden of disease and management in 5 EU countries
P Kanavos, S van den Aardweg, W Schurer
LSE Health and Social Care, 50, 2012
2132012
Early chronic kidney disease: diagnosis, management and models of care
OJ Wouters, DJ O'donoghue, J Ritchie, PG Kanavos, AS Narva
Nature Reviews Nephrology 11 (8), 491-502, 2015
1822015
Socio-economic burden of rare diseases: a systematic review of cost of illness evidence
A Angelis, D Tordrup, P Kanavos
Health Policy 119 (7), 964-979, 2015
1822015
Competition in off-patent drug markets: Issues, regulation and evidence
P Kanavos, J Costa-Font, E Seeley
Economic policy 23 (55), 500-544, 2008
1742008
Reference pricing for drugs: is it compatible with US health care?
P Kanavos, U Reinhardt
Health Affairs 22 (3), 16-30, 2003
1582003
Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom
SG Morgan, M McMahon, C Mitton, E Roughead, R Kirk, P Kanavos, ...
Health Affairs 25 (2), 337-347, 2006
1552006
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
A Ferrario, P Kanavos
Social science & medicine 124, 39-47, 2015
1342015
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
A Angelis, A Lange, P Kanavos
The European Journal of Health Economics 19 (1), 123-152, 2018
1322018
Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review
AD Bertoldi, P Kanavos, GVA França, A Carraro, CAO Tejada, PC Hallal, ...
Globalization and health 9 (1), 1-12, 2013
1322013
Managed entry agreements for pharmaceuticals: the European experience
A Ferrario, P Kanavos
EMINet, 2013
1292013
Pharmaceutical parallel trade in Europe: stakeholder and competition effects
P Kanavos, J Costa-Font
Economic policy 20 (44), 758-798, 2005
1292005
Multiple criteria decision analysis (MCDA) for evaluating new medicines in health technology assessment and beyond: the advance value framework
A Angelis, P Kanavos
Social Science & Medicine 188, 137-156, 2017
1252017
Do generics offer significant savings to the UK National Health Service?
P Kanavos
Current medical research and opinion 23 (1), 105-116, 2007
1122007
Symptomatic vitreomacular adhesion
TL Jackson, E Nicod, A Simpson, A Angelis, F Grimaccia, P Kanavos
Retina 33 (8), 1503-1511, 2013
1062013
Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs
P Kanavos, A Ferrario, S Vandoros, GF Anderson
Health affairs 32 (4), 753-761, 2013
1062013
Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy
TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ...
Retina 33 (10), 2012-2017, 2013
1042013
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20